An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease

The gut microbiota is associated with metabolic diseases including obesity, insulin resistance, and nonalcoholic fatty liver disease, as shown by correlative studies and by transplant of microbiota from obese humans and mice into germ-free mice. Modification of the microbiota by treatment of high-fat diet (HFD)-fed mice with tempol or antibiotics resulted in decreased adverse metabolic phenotypes. This was owing to lower levels of the genera Lactobacillus and decreased bile salt hydrolase (BSH) activity. The decreased BSH resulted in increased levels of tauro-β-muricholic acid (MCA), a substrate of BSH and a potent farnesoid X receptor (FXR) antagonist. Mice lacking expression of FXR in the intestine were resistant to HFD-induced obesity, insulin resistance, and nonalcoholic fatty liver disease, thus confirming that intestinal FXR is involved in the potentiation of metabolic disease. A potent intestinal FXR antagonist, glycine-β-MCA (Gly-MCA), which is resistant to BSH, was developed, which, when administered to HFD-treated mice, mimics the effect of the altered microbiota on HFD-induced metabolic disease. Gly-MCA had similar effects on genetically obese leptin-deficient mice. The decrease in adverse metabolic phenotype by tempol, antibiotics, and Gly-MCA was caused by decreased serum ceramides. Mice lacking FXR in the intestine also have lower serum ceramide levels, and are resistant to HFD-induced metabolic disease, and this was reversed by injection of C16:0 ceramide. In mouse ileum, because of the presence of endogenous FXR agonists produced in the liver, FXR target genes involved in ceramide synthesis are activated and when Gly-MCA is administered they are repressed, which likely accounts for the decrease in serum ceramides. These studies show that ceramides produced in the ileum under control of FXR influence metabolic diseases. The gut microbiota is associated with metabolic diseases including obesity, insulin resistance, and nonalcoholic fatty liver disease, as shown by correlative studies and by transplant of microbiota from obese humans and mice into germ-free mice. Modification of the microbiota by treatment of high-fat diet (HFD)-fed mice with tempol or antibiotics resulted in decreased adverse metabolic phenotypes. This was owing to lower levels of the genera Lactobacillus and decreased bile salt hydrolase (BSH) activity. The decreased BSH resulted in increased levels of tauro-β-muricholic acid (MCA), a substrate of BSH and a potent farnesoid X receptor (FXR) antagonist. Mice lacking expression of FXR in the intestine were resistant to HFD-induced obesity, insulin resistance, and nonalcoholic fatty liver disease, thus confirming that intestinal FXR is involved in the potentiation of metabolic disease. A potent intestinal FXR antagonist, glycine-β-MCA (Gly-MCA), which is resistant to BSH, was developed, which, when administered to HFD-treated mice, mimics the effect of the altered microbiota on HFD-induced metabolic disease. Gly-MCA had similar effects on genetically obese leptin-deficient mice. The decrease in adverse metabolic phenotype by tempol, antibiotics, and Gly-MCA was caused by decreased serum ceramides. Mice lacking FXR in the intestine also have lower serum ceramide levels, and are resistant to HFD-induced metabolic disease, and this was reversed by injection of C16:0 ceramide. In mouse ileum, because of the presence of endogenous FXR agonists produced in the liver, FXR target genes involved in ceramide synthesis are activated and when Gly-MCA is administered they are repressed, which likely accounts for the decrease in serum ceramides. These studies show that ceramides produced in the ileum under control of FXR influence metabolic diseases. The accumulation of ectopic triglycerides in the liver, in the absence of other liver disease or chronic alcohol consumption, is termed nonalcoholic fatty liver disease (NAFLD).1Chalasani N. Younossi Z. Lavine J.E. et al.The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Hepatology. 2012; 55: 2005-2023Google Scholar, 2Sattar N. Forrest E. Preiss D. Non-alcoholic fatty liver disease.BMJ. 2014; 349: g4596Google Scholar NAFLD affects approximately 19% of the adult population, and is correlated with the worldwide epidemic of metabolic disease that is associated with concurrent obesity and insulin resistance.3Younossi Z.M. Stepanova M. Negro F. et al.Nonalcoholic fatty liver disease in lean individuals in the United States.Medicine (Baltimore). 2012; 91: 319-327Google Scholar Patients with obesity, type 2 diabetes, dyslipidemia, high blood pressure, and NAFLD are characterized as having metabolic syndrome,4Grundy S.M. Metabolic syndrome update.Trends Cardiovasc Med. 2016; 26: 364-373Google Scholar and, alarmingly, this classification applies equally to children as well as adults.5Michail S. Lin M. Frey M.R. et al.Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.FEMS Microbiol Ecol. 2015; 91: 1-9Google Scholar Persistent NAFLD can lead to nonalcoholic steatohepatitis (NASH), in which fibrosis develops on top of steatosis and is characterized histologically by hepatocyte ballooning, degeneration, and inflammation. Fibrosis, although not always observed, is caused by chronic inflammation and oxidative stress that occurs in the presence of increased hepatic lipids. NASH is associated with an additional increased risk of developing cirrhosis and hepatocellular carcinoma.6Baffy G. Brunt E.M. Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.J Hepatol. 2012; 56: 1384-1391Google Scholar, 7Dyson J. Day C. Treatment of non-alcoholic fatty liver disease.Dig Dis. 2014; 32: 597-604Google Scholar NAFLD is linked not only to obesity and insulin resistance, but also to heart disease and atherosclerosis, and there is a significant population (mostly Asian) of metabolically normal individuals with NAFLD, which suggests a genetic or environmental influence to this disease.8Loomba R. Sanyal A.J. The global NAFLD epidemic.Nat Rev Gastroenterol Hepatol. 2013; 10: 686-690Google Scholar NAFLD often is called the silent disease because of a lack of clear symptoms that makes it especially dangerous because it is not diagnosed easily. Thus, major efforts have been undertaken to determine the cause of NAFLD, to develop new therapeutic interventions, and to establish curative strategies for NAFLD.9Bhatia L.S. Curzen N.P. Calder P.C. et al.Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?.Eur Heart J. 2012; 33: 1190-1200Google Scholar Although the molecular mechanisms of NAFLD pathogenesis have been investigated extensively, there are few clues for the identification of novel targets that can be exploited for NAFLD therapy, and thus this remains an area of high priority. Accumulating evidence suggests that intestinal bacteria contribute to the development of NAFLD10Aqel B. DiBaise J.K. Role of the gut microbiome in nonalcoholic fatty liver disease.Nutr Clin Pract. 2015; 30: 780-786Google Scholar based on observations in a variety of animal models11Le Roy T. Llopis M. Lepage P. et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice.Gut. 2013; 62: 1787-1794Google Scholar as well as in humans.5Michail S. Lin M. Frey M.R. et al.Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.FEMS Microbiol Ecol. 2015; 91: 1-9Google Scholar, 12Del Chierico F. Nobili V. Vernocchi P. et al.Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach.Hepatology. 2016; (Epub ahead of print)Google Scholar, 13Boursier J. Mueller O. Barret M. et al.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology. 2016; 63: 764-775Google Scholar Intestinal bacteria also influence obesity and insulin resistance.14Turnbaugh P.J. Ley R.E. Mahowald M.A. et al.An obesity-associated gut microbiome with increased capacity for energy harvest.Nature. 2006; 444: 1027-1031Google Scholar, 15Arora T. Backhed F. The gut microbiota and metabolic disease: current understanding and future perspectives.J Intern Med. 2016; 280: 339-349Google Scholar Bacteria community analysis, based on 16S ribosomal RNA gene sequencing, has shown stark differences between metabolically normal individuals and those with NAFLD and NASH. Broad phyla level (noted shifts in Bacteroidetes, Firmicutes, and Proteobacteria) changes have been reported and some investigators have attempted to implicate specific bacterial strains with disease, although these observations remain preliminary.16Ng M. Fleming T. Robinson M. et al.Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2014; 384: 766-781Google Scholar, 17De Minicis S. Rychlicki C. Agostinelli L. et al.Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice.Hepatology. 2014; 59: 1738-1749Google Scholar, 18Elshaghabee F.M. Bockelmann W. Meske D. et al.Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions.Front Microbiol. 2016; 7: 47Google Scholar Interestingly, stool bacterial community profiles of children with NAFLD are unique compared with adults with NAFLD, but this inconsistency might be expected given observations from others.19Yatsunenko T. Rey F.E. Manary M.J. et al.Human gut microbiome viewed across age and geography.Nature. 2012; 486: 222-227Google Scholar By using longitudinal sequencing of samples collected over time, it is clear that the gut microbiota is dynamic and ever-changing throughout childhood, and only stabilizes once adulthood is reached.19Yatsunenko T. Rey F.E. Manary M.J. et al.Human gut microbiome viewed across age and geography.Nature. 2012; 486: 222-227Google Scholar These observations suggest that at the gut bacteria level, NAFLD therapies might need to be tailored based on age, and underscores that the gut microbiota contribution in children may be significantly different in adults. However, it should be noted that these studies are far from complete because the conclusions typically have been derived from small sample sizes and have not been evaluated in other cohorts. It is clear that more long-term studies representing different ages, sexes, and ethnic groups will be essential to understand the complex etiology of this disease. Some of the strongest data linking gut bacteria with NAFLD comes from studies examining the impact of antibiotic treatment on NAFLD pathogenesis and progression. Interestingly, remarkably different outcomes were reported depending on the timing, duration, and dose of antibiotic used either to promote or treat NAFLD. For example, a recent report suggested that chronic exposure to penicillin G (6.8 mg/L in the drinking water) in combination with a high-fat diet (HFD) (45% kcal from fat) resulted not only in metabolic disturbances but also gut dysbiosis, which was suggested to be a strong promoter of NAFLD.20Mahana D. Trent C.M. Kurtz Z.D. et al.Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet.Genome Med. 2016; 8: 48Google Scholar This and other studies underscore that early and sustained perturbation of the gut microbiota is associated strongly with metabolic diseases including obesity and NAFLD.21Nobel Y.R. Cox L.M. Kirigin F.F. et al.Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment.Nat Commun. 2015; 6: 7486Google Scholar, 22Cox L.M. Yamanishi S. Sohn J. et al.Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences.Cell. 2014; 158: 705-721Google Scholar However, other reports have suggested that germ-free mice are fully resistant to the development of NAFLD (as well as obesity and other related metabolic disorders),23Suarez-Zamorano N. Fabbiano S. Chevalier C. et al.Microbiota depletion promotes browning of white adipose tissue and reduces obesity.Nat Med. 2015; 21: 1497-1501Google Scholar and that a high dose cocktails of antibiotics can reverse NAFLD.24Jiang C. Xie C. Li F. et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.J Clin Invest. 2015; 125: 386-402Google Scholar Moreover, antibiotics such as rifaximin with poor bioavailability and hence likely to impact only the gut microbiota, were shown to be efficacious against NAFLD in humans.25Gangarapu V. Ince A.T. Baysal B. et al.Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.Eur J Gastroenterol Hepatol. 2015; 27: 840-845Google Scholar Antibiotic treatment even may help to prevent the transition toward hepatocellular carcinoma.26Yoshimoto S. Loo T.M. Atarashi K. et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature. 2013; 499: 97-101Google Scholar Although data from low- and high-dose antibiotic use appear to be contradicting, differences in dose, exposure window, and choice of antibiotic likely direct metabolic processes in the host and gut microbiota either toward health or disease. The gut microbiota has been implicated directly in the development of obesity and NAFLD in mice and in humans.27Park J.S. Seo J.H. Youn H.S. Gut microbiota and clinical disease: obesity and nonalcoholic fatty liver disease.Pediatr Gastroenterol Hepatol Nutr. 2013; 16: 22-27Google Scholar, 28Nguyen T.L. Vieira-Silva S. Liston A. et al.How informative is the mouse for human gut microbiota research?.Dis Model Mech. 2015; 8: 1-16Google Scholar, 29Quigley E.M. Monsour H.P. The gut microbiota and nonalcoholic fatty liver disease.Semin Liver Dis. 2015; 35: 262-269Google Scholar Notably, in transplant studies, when lean germ-free mice were treated with the cecal microbiota from obese mice, there was an increase in hepatic triglyceride accumulation.30Bäckhed F. Ding H. Wang T. et al.The gut microbiota as an environmental factor that regulates fat storage.Proc Natl Acad Sci U S A. 2004; 101: 15718-15723Google Scholar When bacteria from lean humans were transferred to germ-free mice, the mice became resistant to obesity, whereas mice receiving bacteria from obese humans were prone to obesity.31Ridaura V.K. Faith J.J. Rey F.E. et al.Gut microbiota from twins discordant for obesity modulate metabolism in mice.Science. 2013; 341: 1241214Google Scholar Although it was not measured directly, this correlation also may have extended to insulin resistance and NAFLD, which are associated directly with obesity. Indeed, another study showed that mice receiving bacteria transplanted from their obese counterparts developed hepatic macrovesicular steatosis and showed increased expression of the genes involved in lipid synthesis.11Le Roy T. Llopis M. Lepage P. et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice.Gut. 2013; 62: 1787-1794Google Scholar Correlative studies of gut bacteria transplantation have shown a direct relationship between various genera of bacteria and metabolic disease that may yield hints to their mechanism.11Le Roy T. Llopis M. Lepage P. et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice.Gut. 2013; 62: 1787-1794Google Scholar For example, obese humans show an enrichment of the energy-harvesting phylum Firmicutes, which have an improved energy yield from intestinal contents (eg, short-chain fatty acids including acetate, butyrate, and propionate) that are thought to accelerate obesity and NAFLD, mostly likely through de novo lipogenesis pathways.14Turnbaugh P.J. Ley R.E. Mahowald M.A. et al.An obesity-associated gut microbiome with increased capacity for energy harvest.Nature. 2006; 444: 1027-1031Google Scholar In a study of NAFLD patients, there was an over-representation of Lactobacillus species and members of the phylum Firmicutes, thus establishing a potential role for gut microbiota in human NAFLD.32Raman M. Ahmed I. Gillevet P.M. et al.Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2013; 11 (e1–3): 868-875Google Scholar Although there is an association between populations of gut microbiota and even metabolism in NAFLD, it remains uncertain whether the altered bacteria (as compared with lean individuals) cause obesity or are caused by obesity.33Dumas M.E. Barton R.H. Toye A. et al.Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.Proc Natl Acad Sci U S A. 2006; 103: 12511-12516Google Scholar, 34Spencer M.D. Hamp T.J. Reid R.W. et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency.Gastroenterology. 2011; 140: 976-986Google Scholar Overall, the gut microbiota was shown to significantly influence, and itself can be shaped by, metabolic diseases such as obesity and type 2 diabetes.10Aqel B. DiBaise J.K. Role of the gut microbiome in nonalcoholic fatty liver disease.Nutr Clin Pract. 2015; 30: 780-786Google Scholar, 35Barlow G.M. Yu A. Mathur R. Role of the gut microbiome in obesity and diabetes mellitus.Nutr Clin Pract. 2015; 30: 787-797Google Scholar Adding to the complexity in understanding their contribution to NAFLD and other metabolic disease, intestinal bacteria populations vary considerably, depending on factors such as host genetics and health, the environment, and diet.36Sonnenburg J.L. Backhed F. Diet-microbiota interactions as moderators of human metabolism.Nature. 2016; 535: 56-64Google Scholar These variations contribute to an individual's metabolic phenotype or metabotype.37Claus S.P. Tsang T.M. Wang Y. et al.Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes.Mol Syst Biol. 2008; 4: 219Google Scholar, 38Waldram A. Holmes E. Wang Y. et al.Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents.J Proteome Res. 2009; 8: 2361-2375Google Scholar, 39Lozupone C.A. Stombaugh J.I. Gordon J.I. et al.Diversity, stability and resilience of the human gut microbiota.Nature. 2012; 489: 220-230Google Scholar, 40Patterson A.D. Turnbaugh P.J. Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology.Cell Metab. 2014; 20: 761-768Google Scholar Gut bacteria can be involved directly in the metabolism of dietary compounds such as lipids, polysaccharides, and xenobiotics, and can influence the uptake of nutrients, which may contribute to host metabolism and metabolic disease. Notably, gut bacteria metabolize bile acids that are produced in the liver, and can metabolize many drugs.40Patterson A.D. Turnbaugh P.J. Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology.Cell Metab. 2014; 20: 761-768Google Scholar, 41Fang Z.Z. Zhang D. Cao Y.F. et al.Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression.Toxicol Appl Pharmacol. 2015; 291: 21-27Google Scholar Bile acid metabolites may in part mediate the influence of the microbiota on metabolic disease and also may mediate changes in the composition of the gut bacteria.42Wahlstrom A. Sayin S.I. Marschall H.U. et al.Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism.Cell Metab. 2016; 24: 41-50Google Scholar, 43Parseus A. Sommer N. Sommer F. et al.Microbiota-induced obesity requires farnesoid X receptor.Gut. 2016; (Epub ahead of print)Google Scholar Bile acids are produced in the liver by the oxidation of cholesterol through a series of reactions performed by cytochrome P450s (CYP), with cholesterol 7α-hydroxylase (CYP7A1) generally considered the rate-limiting enzyme that initiates bile acid synthesis.44Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis.Annu Rev Biochem. 2003; 72: 137-174Google Scholar, 45Chiang J.Y. Bile acids: regulation of synthesis.J Lipid Res. 2009; 50: 1955-1966Google Scholar After modification by oxidation, most bile acids undergo conjugation with the amino acids taurine and glycine before being transported to the intestine through the canaliculi that merge and form the bile duct.46Hofmann A.F. The enterohepatic circulation of bile acids in mammals: form and functions.Front Biosci (Landmark Ed). 2009; 14: 2584-2598Google Scholar Taurine conjugation predominantly occurs in mice, whereas glycine conjugation occurs in hamsters and humans; both taurine and glycine conjugation occurs in rats.47Sakakura H. Kimura N. Takeda H. et al.Simultaneous determination of bile acids in rat liver tissue by high-performance liquid chromatography.J Chromatogr B Biomed Sci Appl. 1998; 718: 33-40Google Scholar Conjugated and unconjugated bile acids are transported out of the liver and form micelles in the small intestine that capture dietary lipids and fat-soluble vitamins from the diet, to facilitate their movement down the gastrointestinal tract, and promote their metabolism by intestinal lipases and uptake by the epithelial cells before transport to the bloodstream. Most bile acids leave the liver in the conjugated form, and in the lower small intestine they are deconjugated and further metabolized by gut bacteria. Subsequently, approximately 95% of the bile acids are reabsorbed and transported back to the liver, thus completing the process of enterohepatic circulation.46Hofmann A.F. The enterohepatic circulation of bile acids in mammals: form and functions.Front Biosci (Landmark Ed). 2009; 14: 2584-2598Google Scholar, 48Gonzalez F.J. Nuclear receptor control of enterohepatic circulation.Compr Physiol. 2012; 2: 2811-2828Google Scholar, 49Matsubara T. Li F. Gonzalez F.J. FXR signaling in the enterohepatic system.Mol Cell Endocrinol. 2013; 368: 17-29Google Scholar Bile acid synthesis and enterohepatic circulation are under tight control by receptors that modulate the expression of genes encoding enzymes and proteins involved in bile acid synthesis and transport.48Gonzalez F.J. Nuclear receptor control of enterohepatic circulation.Compr Physiol. 2012; 2: 2811-2828Google Scholar, 49Matsubara T. Li F. Gonzalez F.J. FXR signaling in the enterohepatic system.Mol Cell Endocrinol. 2013; 368: 17-29Google Scholar, 50Stanimirov B. Stankov K. Mikov M. Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases.Hepatobiliary Pancreat Dis Int. 2015; 14: 18-33Google Scholar The major regulator of bile acid homeostasis is the farnesoid X receptor (FXR; NR1H4), a ligand-activated member of the nuclear receptor superfamily.51Forman B.M. Goode E. Chen J. et al.Identification of a nuclear receptor that is activated by farnesol metabolites.Cell. 1995; 81: 687-693Google Scholar, 52Seol W. Choi H.S. Moore D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors.Mol Endocrinol. 1995; 9: 72-85Google Scholar FXR can be bound by a number of endogenous bile acids, including chenodeoxycholic acid (CDCA), taurocholic acid (TCA), deoxycholic acid (DCA), lithocholic acid (LCA), cholic acid (CA), and muricholic acid at various affinities,53Makishima M. Okamoto A.Y. Repa J.J. et al.Identification of a nuclear receptor for bile acids.Science. 1999; 284: 1362-1365Google Scholar, 54Parks D.J. Blanchard S.G. Bledsoe R.K. et al.Bile acids: natural ligands for an orphan nuclear receptor.Science. 1999; 284: 1365-1368Google Scholar with the potency of FXR activation in reporter gene assays estimated as follows: CDCA > LCA = DCA.53Makishima M. Okamoto A.Y. Repa J.J. et al.Identification of a nuclear receptor for bile acids.Science. 1999; 284: 1362-1365Google Scholar Conjugated bile acids such as glycochenodeoxycholic acid, TCA, and taurochenodeoxycholic acid also weakly activate FXR.55Vaquero J. Monte M.J. Dominguez M. et al.Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.Biochem Pharmacol. 2013; 86: 926-939Google Scholar FXR is expressed in the liver and intestine where it regulates the expression of genes involved in the synthesis and transport of bile acids, and thus is a major modulator of bile acid homeostasis and enterohepatic circulation.48Gonzalez F.J. Nuclear receptor control of enterohepatic circulation.Compr Physiol. 2012; 2: 2811-2828Google Scholar, 49Matsubara T. Li F. Gonzalez F.J. FXR signaling in the enterohepatic system.Mol Cell Endocrinol. 2013; 368: 17-29Google Scholar In the presence of increased intracellular bile acids, hepatic FXR is activated, resulting in the suppression of bile acid synthesis, enhanced bile acid bile transport to the small intestine, and reduced bile acid uptake from the blood. FXR-mediated gene suppression occurs through the induction of small heterodimer partner ([SHP]; NR0B2), which interferes with the positive regulation of gene expression by other nuclear receptors including liver-receptor homolog-1 (NR5A2) and liver X receptor (NR1H3), both of which control the expression of genes involved in bile acid synthesis, notably CYP7A1, and transport.56Zhang Y. Hagedorn C.H. Wang L. Role of nuclear receptor SHP in metabolism and cancer.Biochim Biophys Acta. 2011; 1812: 893-908Google Scholar Interestingly, liver X receptor controls the mouse and rat genes encoding CYP7A1, but does not control the corresponding human CYP7A1 gene.57Chen J.Y. Levy-Wilson B. Goodart S. et al.Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet.J Biol Chem. 2002; 277: 42588-42595Google Scholar Hepatocyte nuclear factor 4α (NR2A21) is also a key regulator of CYP7A1, bile acid conjugation enzymes, and several transporters.58Chiang J.Y. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism.Expert Opin Drug Metab Toxicol. 2009; 5: 137-147Google Scholar In the intestine, activation of FXR by increased levels of bile acids in the enterocyte results in enhanced transport of bile acids to the blood and uptake by the liver, and decreased bile acid synthesis in the liver through induction of fibroblast growth factor (FGF)19 (FGF15 in mice) expression in the enterocyte, which upon transport to the liver and activation of the FGF receptor 4/β-Klotho–receptor complex on the hepatocyte plasma membrane, also suppresses the expression of CYP7A1 as recently reviewed.59Kliewer S.A. Mangelsdorf D.J. Bile acids as hormones: The FXR-FGF15/19 pathway.Dig Dis. 2015; 33: 327-331Google Scholar Hepatic FXR inhibits the expression of sodium ion/bile acid cotransporter, which transports bile acid into the liver and activates expression of the bile salt export protein (ABCb11), which transports bile acids across the canalicular membrane into the bile duct and gall bladder.60Kullak-Ublick G.A. Stieger B. Meier P.J. Enterohepatic bile salt transporters in normal physiology and liver disease.Gastroenterology. 2004; 126: 322-342Google Scholar Ileal FXR controls bile acid uptake from the small intestine to the portal blood through induction of apical sodium-dependent bile acid transporter (ASBT) (SLC10A2), which transports bile acids into the epithelial cells, ileal fatty acid binding protein 6 (I-BABP; FABP6), which transports in the bile acids across the cell, and organic solute transporter α/β (OSTα/β) (SLC51A/B), which transports bile acids into the portal blood.61Dawson P.A. Role of the intestinal bile acid transporters in bile acid and drug disposition.Handb Exp Pharmacol. 2011; 201: 169-203Google Scholar FGF15/19 also promotes the emptying of the gall bladder through binding and activating the FGF receptor 2/β-Klotho–receptor complex.59Kliewer S.A. Mangelsdorf D.J. Bile acids as hormones: The FXR-FGF15/19 pathway.Dig Dis. 2015; 33: 327-331Google Scholar Thus, in summary, under conditions of increased bile acid levels in the intestine, FXR is activated in the epithelial cells of the ileum and stimulates the transport of bile acids into the portal blood for delivery back to the liver. Increased hepatic bile acids activate FXR to increase the export of bile acids into the intestine, decrease uptake of bile acids from the blood, and decrease bile acid synthesis. Intestinal FXR activation further increases FXR15/19 to decrease bile acid synthesis in the liver by suppression of CYP7A1 expression. Through mechanisms that still are not well understood, FXR also regulates lipid and glucose levels in the liver and serum,62Cipriani S. Mencarelli A. Palladino G. et al.FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.J Lipid Res. 2010; 51: 771-784Google Scholar, 63Porez G. Prawitt J. Gross B. et al.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.J Lipid Res. 2012; 53: 1723-1737Google Scholar and influences cardiovascular disease.64Mencarelli A. Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis.J Cell Mol Med. 2010; 14: 79-92Google Scholar A G-protein–coupled receptor, Takeda G-protein–coupled receptor-5 (TGR5; GPBAR1) also responds to bile acid ligands produced in the liver.50Stanimirov B. Stankov K. Mikov M. Bile acid signaling through farnesoid X and TGR5 re